Halothane biotransformation in obese and nonobese patients

Area of Science:

• Anesthesiology
• Clinical Chemistry
• Pharmacology

Background:

• Halothane anesthesia is widely used but can undergo reductive metabolism.
• Reductive halothane metabolism is associated with hepatotoxicity in animal models.
• Obesity may influence drug metabolism and patient outcomes.

Purpose of the Study:

• To investigate serum levels of halothane metabolites in morbidly obese versus nonobese patients.
• To assess the impact of obesity on halothane metabolism and potential toxicity markers.
• To determine if patient factors like sex, age, or smoking influence metabolite levels.

Main Methods:

• Serum samples were collected from 17 morbidly obese and 8 nonobese patients at various time points after 2-hour halothane anesthesia.
• Levels of inorganic fluoride, trifluoroacetic acid, and bromide ion were quantified.
• Statistical analysis was performed to compare metabolite levels between the obese and nonobese groups.

Main Results:

• Obese patients exhibited increased serum inorganic fluoride levels, indicating enhanced reductive halothane metabolism.
• Serum bromide levels were significantly higher in obese patients at 48 hours post-anesthesia.
• Peak trifluoroacetic acid levels and the influence of sex, age, medication, or smoking were similar between groups.

Conclusions:

• Morbidly obese patients may be at increased risk due to enhanced reductive halothane metabolism.
• Elevated bromide levels in obese patients warrant further investigation.
• Obesity appears to be a significant factor affecting halothane metabolite profiles.